Startup entity
acquisition is the sole category represented across all 1 tracked stories. Scantox is most often covered alongside DuplexSeq, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 4.5 for the broader beat in this window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. Scantox is most often covered alongside DuplexSeq, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 4.5 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.9. We currently track 1 Startup story that mention Scantox, all published on February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 42 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Scantox. Shared-story counts are live from our verified record — not editorial picks.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive DNA sequencing technology into its preclinical CRO services. The move positions Scantox as a leader in high-precision genetic toxicology, offering pharmaceutical clients 10,000x greater sensitivity in identifying mutagenic risks.
Scantox is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
